Venous Thromboembolism

60

Pipeline Programs↗

25

Active Trials↗

23

Companies Involved↗

Venous Thromboembolism is a moderately active landscape with 60 programs across 23 companies. The most active players are Beijing Suncadia Pharmaceuticals Co., Ltd, Astellas, LEO Pharma. 19 therapies are approved with 22 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

19/100

Mech. Concentration

25/100

Completion Rate

81/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Beijing Suncadia Pharmaceuticals Co., Ltd

2 programs

Astellas

1 program

LEO Pharma

1 program

Regeneron

1 program

Dexcel Pharma Technologies Ltd.

1 program

Keryx Biopharmaceuticals

1 program

Analysis

Trial Status

155

clinical trials

Completed94 · 61%

Terminated18 · 12%

Recruiting14 · 9%

Unknown status14 · 9%

Not yet recruiting6 · 4%

Withdrawn4 · 3%

Other5 · 3%

Clinical Trials

Trial Activity

155 trials

Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients

Recruiting·PPeking Union Medical College Hospital·N/A·NCT06194617·300 enrolled

Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

Recruiting·—·Phase 3·NCT05627375·1,400 enrolled

Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery

Recruiting·—·N/A·NCT06689241·162 enrolled

Venous Thromboembolism Prevention in Outpatients With Glioma

Recruiting·UUniversity of Vermont Medical Center·Phase 2·NCT05683808·40 enrolled

Statins for Venous Event Reduction in Patients With Venous Thromboembolism

Recruiting·OOttawa Hospital Research Institute·Phase 3·NCT04319627·2,700 enrolled

Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

Recruiting·AArianna Anticoagulazione Foundation·Phase 3·NCT04257487·1,455 enrolled

A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT06866964·35 enrolled

Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism

Recruiting·OOttawa Hospital Research Institute·Phase 3·NCT06393868·360 enrolled

Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk

Recruiting·UUniversity Hospital, Brest·Phase 4·NCT06845423·2,400 enrolled

PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)

Recruiting·SSunnybrook Health Sciences Centre·Phase 3·NCT03559114·1,100 enrolled

Ongoing Registry of Treatment of Venous Thromboembolism

Recruiting·MMedalp Private Surgery Clinic·N/A·NCT03881345·5,000 enrolled

DEFIANCE - ClotTriever® Thrombectomy System vs. Anticoagulation Alone for Treatment of Deep Vein Thrombosis

Recruiting·IInari Medical·Preclinical·NCT05701917·300 enrolled

RIVACAST : RIVAroxaban Versus Low-molecular Weight Heparinin Patients With Lower Limb Trauma Requiring Brace or CASTing

Recruiting·UUniversity Hospital, Angers·Phase 3·NCT06195540·1,424 enrolled

Variations in the Hemostatic System Induced by a Standardized Walking Test: Controls vs. Cases With a History of Non-anticoagulated Venous Thromboembolic Disease

Recruiting·CCentre Hospitalier Universitaire de Nīmes·Preclinical·NCT06418633·94 enrolled

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

Active, not recruiting·HHerlev and Gentofte Hospital·Phase 4·NCT03129555·5,000 enrolled

Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)